S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
NASDAQ:DNTH

Dianthus Therapeutics (DNTH) Stock Price, News & Analysis

$23.25
-0.38 (-1.61%)
(As of 04/19/2024 ET)
Today's Range
$23.14
$24.66
50-Day Range
$22.82
$31.94
52-Week Range
$6.58
$33.77
Volume
164,538 shs
Average Volume
143,527 shs
Market Capitalization
$682.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.40

Dianthus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.4% Upside
$42.40 Price Target
Short Interest
Bearish
6.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of Dianthus Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.92) to ($2.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.23 out of 5 stars

Medical Sector

743rd out of 911 stocks

Pharmaceutical Preparations Industry

329th out of 411 stocks

DNTH stock logo

About Dianthus Therapeutics Stock (NASDAQ:DNTH)

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

DNTH Stock Price History

DNTH Stock News Headlines

What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Dianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading Volume
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
EQ Apr 2024 5.000 put
Dianthus Therapeutics Inc DNTH
SMCI Jan 2025 1310.000 call
SMCI Mar 2024 1070.000 call
Dianthus Therapeutics Announces $230 Million Private Placement
See More Headlines
Receive DNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/19/2024
Next Earnings (Estimated)
6/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DNTH
Fax
N/A
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$42.40
High Stock Price Target
$51.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+82.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-43,560,000.00
Pretax Margin
-1,541.22%

Debt

Sales & Book Value

Annual Sales
$2.83 million
Book Value
$11.40 per share

Miscellaneous

Free Float
25,956,000
Market Cap
$682.39 million
Optionable
No Data
Beta
1.68
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Marino Garcia M.B.A. (Age 58)
    President, CEO, Secretary & Director
  • Mr. Edward G. Carr (Age 55)
    Chief Accounting Officer
  • Mr. Judson Taylor
    Head of Technical Operations
  • Dr. Jeffrey Stavenhagen Ph.D.
    Chief Scientific Officer
  • Ms. Jennifer Davis Ruff
    VP and Head of Investor Relations & Corporate Affairs.
  • Ms. Kristina Maximenko
    Chief People Officer
  • Ms. Rashieda Gluck
    Head of Clinical Development Operations
  • Mr. Scott Nogi M.B.A.
    Head of Business Operations
  • Ms. Debra Segal
    Head of Regulatory Affairs
  • Ms. Polly Hanff
    Head of Quality

DNTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Dianthus Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dianthus Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DNTH shares.
View DNTH analyst ratings
or view top-rated stocks.

What is Dianthus Therapeutics' stock price target for 2024?

5 brokers have issued 12-month price objectives for Dianthus Therapeutics' stock. Their DNTH share price targets range from $33.00 to $51.00. On average, they predict the company's stock price to reach $42.40 in the next twelve months. This suggests a possible upside of 82.4% from the stock's current price.
View analysts price targets for DNTH
or view top-rated stocks among Wall Street analysts.

How have DNTH shares performed in 2024?

Dianthus Therapeutics' stock was trading at $10.40 on January 1st, 2024. Since then, DNTH shares have increased by 123.6% and is now trading at $23.25.
View the best growth stocks for 2024 here
.

Are investors shorting Dianthus Therapeutics?

Dianthus Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,390,000 shares, an increase of 29.9% from the March 15th total of 1,070,000 shares. Based on an average trading volume of 141,400 shares, the short-interest ratio is currently 9.8 days. Approximately 6.5% of the company's stock are sold short.
View Dianthus Therapeutics' Short Interest
.

When is Dianthus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 20th 2024.
View our DNTH earnings forecast
.

How were Dianthus Therapeutics' earnings last quarter?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.40. The firm earned $0.46 million during the quarter, compared to the consensus estimate of $0.73 million.

How do I buy shares of Dianthus Therapeutics?

Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DNTH) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners